新疆医科大学学报

参考文献

[1] LIN N,SUN X,ZHOU H,et al.Loncastuximab tesirine in Chinese patients with relapsedor refractory diffuse large B-cell lymphoma:a multicenter,open-label,single-arm,phase II trial[J].Haematologica,2025,110(3):683-692.

[2] NASTOUPIL L J,BARTLETT N L.Navigating the evolving treatment landscape of diffuse large B-cell lymphoma[J].J Clin Oncol,2022,41(4):903-913.

[3] 张箫扬子，祝永福，梅旦.弥漫性大B细胞淋巴瘤的病理机制及其免疫治疗的研究进展[J].中国临床药理学与治疗学，2025,30(12):1711-1721.

[4] MULDER T A,WAHLIN B E,ÖSTERBORG A,et al.Targeting the immune microenvironment in lymphomas of b-cell origin:from biology to clinical application[J].Cancers(Basel),2019,11(7):915.

[5] SERAG EL-DIEN M M,ABDOU A G,ASAAD N Y,et al.Intratumoral FOXP3+ regulatory T cells in diffuse large B-cell lymphoma[J].Appl Immunohistochem Mol Morphol,2017,25(8):534-542.

[6] ZHONG W,LIU X,ZHU Z,et al.High levels of Tim-3+Foxp3+Treg cells in the tumor microenvironment is a prognostic indicator of poor survival of diffuse large B cell lymphoma patients[J].Int Immunopharmacol,2021,96:107662.

[7] ZHU Q,YANG Y,CHEN K,et al.Diffuse large B-cell lymphoma:the significance of CD8+ tumor-infiltrating lymphocytes exhaustion mediated by TIM3/Galectin-9 pathway[J].J Transl Med,2024,22(1):174.

[8] CHEN Z,DENG X,YE Y,et al.Novel risk stratification of de novo diffuse large B cell lymphoma based on tumour-infiltrating T lymphocytes evaluated by flow cytometry[J].Ann Hematol,2018,98(2):391-399.

[9] LI L,SUN R,MIAO Y,et al.PD-1/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration:a study from the international DLBCL consortium program[J].Mod Pathol,2019,32(6):741-754.

[10] YU M,ZHANG Q,WAN L,et al.IL-1R8 expression in DLBCL regulates NK cell recruitment and influences patient prognosis[J].Funct Integr Genomics,2023,23(4):328.

[11] FREUD A G,MUNDY-BOSSE B L,YU J,et al.The broad spectrum of human natural killer cell diversity[J].Immunity,2017,47(5):820-833.

[12] PHAN M T,CHUN S,KIM S H,et al.Natural killer cell subsets and receptor expression in peripheral blood mononuclear cells of a healthy korean population:reference range,influence of age and sex,and correlation between NK cell receptors and cytotoxicity[J].Hum Immunol,2016,78(2):103-112.

[13] YU T,XU-MONETTE Z Y,LAGOO A,et al.Flow cytometry quantification of tumor-infiltrating lymphocytes to predict the survival of patients with diffuse large B-cell lymphoma[J].Front Immunol,2024,15:1335689.

[14] 王焕焕，董文浩，刘芳，等.肿瘤细胞与肿瘤相关巨噬细胞之间的代谢串扰[J].中国细胞生物学学报，2025,47(11):2959-2971.

[15] KHALIFA K A,BADAWY H M,RADWAN W M,et al.CD14(+) HLA-DR low/(-) monocytes as indicator of disease aggressiveness in B-cell non-hodgkin lymphoma[J].Int J Lab Hematol,2014,36(6):650-655.

[16] MARCHESI F,CIRILLO M,BIANCHI A,et al.High density of CD68+/CD163+ tumour-associated macrophages (M2-TAM) at diagnosis is significantly correlated to unfavorable prognostic factors and to poor clinical outcomes in patients with diffuse large B-cell lymphoma[J].Hematol Oncol,2014,33(2):110-112.

[17] NAM S J,GO H,PAIK J H,et al.An increase of M2 macrophages predicts poor prognosis in patients with diffuse large B-cell lymphoma treated with rituximab,cyclophosphamide,doxorubicin,vincristine and prednisone[J].Leuk Lymphoma,2014,55(11):2466-2476.

[18] RIIHIJÄRVI S,FISKVIK I,TASKINEN M,et al.Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma:a correlative study from a nordic phase II trial[J].Haematologica,2014,100(2):238-245.

[19] 刘威，司瑜，张志钢.肿瘤相关中性粒细胞在肿瘤免疫微环境中的作用及治疗研究进展[J].中国肿瘤，2026,35(01):69-80.

[20] KOUMPIS E,PAPOUDOU-BAI A,PAPATHANASIOU K,et al.Unraveling the immune microenvironment in diffuse large B-cell lymphoma:prognostic and potential therapeutic implications[J].Curr Issues Mol Biol,2024,46(7):7048-7064.

[21] EFSTRATIOU P,DAMIANAKI A,KAVIDOPOULOU A,et al.Myeloid-derived suppressor cells exhibit distinct characteristics in bone marrow and blood of individuals with diffuse large B-cell lymphoma[J].Front Med (Lausanne),2025,11:1515097.

[22] WANG Z,JIANG R,LI Q,et al.Elevated M-MDSCs in circulation are indicative of poor prognosis in diffuse large B-cell lymphoma patients[J].J Clin Med,2021,10(8):1768.

[23] YUAN C T,CHUANG S S,CHENG P Y,et al.Decreased CD11c-positive dendritic cells in the tumor microenvironment predict double-hit/triple-hit genotype and survival in diffuse large B-cell lymphoma[J].J Pathol Clin Res,2022,8(5):436-447.

[24] LENZ G,WRIGHT G,DAVE S S,et al.Stromal gene signatures in large-B-cell lymphomas[J].N Engl J Med,2008,359(22):2313-2323.

[25] 吴雨昕，刘苓霜.肿瘤相关成纤维细胞异质性对肿瘤微环境重塑的影响[J].临床肿瘤学杂志，2025,30(12):1226-1233.

[26] APOLLONIO B,SPADA F,PETROV N,et al.Tumor-activated lymph node fibroblasts suppress T cell function in diffuse large B cell lymphoma[J].J Clin Invest,2023,133(13):e166070.

[27] KOTLOV N,BAGAEV A,REVUELTA M V,et al.Clinical and biological subtypes of b-cell lymphoma revealed by microenvironmental signatures[J].Cancer Discov,2021,11(6):1468-1489.

[28] RIBATTI D,TAMMA R,ANNESE T,et al.Vascular growth in lymphomas:angiogenesis and alternative ways[J].Cancers(Basel),2023,15(12):3262.

[29] RASTEGAR S,KALLEN M,SUSTER D I.Updates in the role of the tumor microenvironment cellular crosstalk and genetic signatures in diffuse large B-cell lymphoma:a narrative review[J].Chin Clin Oncol,2024,13(3):38.

[30] SCHMITZ R,WRIGHT G W,HUANG D W,et al.Genetics and pathogenesis of diffuse large B-cell lymphoma[J].N Engl J Med,2018,378(15):1396-1407.

[31] FANGAZIO M,LADEWIG E,GOMEZ K,et al.Genetic mechanisms of HLA-I loss and immune escape in diffuse large B cell lymphoma[J].Proc Natl Acad Sci USA,2021,118(22):e2104504118.

[32] DENOEUD J,MOSER M.Role of CD27/CD70 pathway of activation in immunity and tolerance[J].J Leukoc Biol,2010,89(2):195-203.

[33] TAKAHARA T,NAKAMURA S,TSUZUKI T,et al.The Immunology of DLBCL[J].Cancers(Basel),2023,15(3):835.

[34] ZHANG J,GU Y,CHEN B.Drug-resistance mechanism and new targeted drugs and treatments of relapse and refractory DLBCL[J].Cancer Manag Res,2023,15:245-255.

[35] KHANMOHAMMADI S,FALLAHTAFTI P.Long non-coding RNA as a novel biomarker and therapeutic target in aggressive B-cell non-Hodgkin lymphoma:a systematic review[J].J Cell Mol Med,2023,27(14):1928-1946.

[36] 李阳.免疫共刺激分子OX40在弥漫大B细胞淋巴瘤中基因表达差异和肿瘤微环境中表达特征及临床预后的研究[D].天津医科大学，2020.

[37] ZHANG T,LU Y,LIU X,et al.Comprehensive analysis of TP53 mutation characteristics and identification of patients with inferior prognosis and enhanced immune escape in diffuse large B-cell lymphoma[J].Am J Hematol,2021,97(1):E14-E17.

[38] WANG J,SANMAMED M F,DATAR I,et al.Fibrinogen-like protein 1 is a major immune inhibitory ligand of LAG-3[J].Cell,2018,176(1-2):334-347.e12.

[39] MA J,YAN S,ZHAO Y,et al.Blockade of PD-1 and LAG-3 expression on CD8+ T cells promotes the tumoricidal effects of CD8+ T cells[J].Front Immunol,2023,14:1265255.

[40] ELADL E,TREMBLAY-LEMAY R,RASTGOO N,et al.Role of CD47 in hematological malignancies[J].J Hematol Oncol,2020,13(1):96.

[41] CHANG J E,SEO S,KIM K M,et al.Rituximab and CHOP chemotherapy plus GM-CSF for previously untreated diffuse large B-cell lymphoma in the elderly:a wisconsin oncology network study[J].Clin Lymphoma Myeloma Leuk,2010,10(5):379-384.

[42] YONEMITSU K,PAN C,FUJIWARA Y,et al.GM-CSF derived from the inflammatory microenvironment potentially enhanced PD-L1 expression on tumor-associated macrophages in human breast cancer[J].Sci Rep,2022,12(1):12007.

[43] XIE Y,YANG H,YANG C,et al.Role and mechanisms of tumor-associated macrophages in hematological malignancies[J].Front Oncol,2022,12:933666.

[44] CHAKRAVARTHY A,KHAN L,BENSLER N P,et al.TGF-β-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure[J].Nat Commun,2018,9(1):4692.

[45] MARTIN C J,DATTA A,LITTLEFIELD C,et al.Selective inhibition of TGFβ1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape[J].Sci Transl Med,2020,12(536):eaay8456.

[46] BINABAJ M M,ASGHARZADEH F,RAHMANI F,et al.Vactosertib potently improves anti-tumor properties of 5-FU for colon cancer[J].Daru,2023,31(2):193-203.

[47] ENNISHI D,TAKATA K,BÉGUELIN W,et al.Molecular and genetic characterization of MHC deficiency identifies EZH2 as therapeutic target for enhancing immune recognition[J].Cancer Discov,2019,9(4):546-563.

[48] MUNAKATA W,SHIRASUGI Y,TOBINAI K,et al.Phase 1 study of tazemetostat in Japanese patients with relapsed or refractory B-cell lymphoma[J].Cancer Sci,2021112(3):1123-1131.

[49] PALOMBA M L,CARTRON G,POPPLEWELL L,et al.Combination of atezolizumab and tazemetostat in patients with relapsed/refractory diffuse large b-cell lymphoma:results from a phase Ib study[J].Clin Lymphoma Myeloma Leuk,2021,22(7):504-512.